










 













 


    Chris Storgard | Ardea Biosciences , Inc. | ZoomInfo.com










 





Chris M Storgard - Rochester, MN | Intelius



























Sign In



We found Chris M Storgard in Rochester, MN


Chris M Storgard

                                                                        Intelius found that Chris M Storgard  from Rochester, MN.  We have connected them to
                4 addresses,
                2 phones,
                and 1 relative or associate.
         






Get Report Now

Chris Has Lived In

Rochester, MN
San Diego, CA
Cambridge, MA

Chris's Relatives

Melinda Storgard







Chris M Storgard



Professional Status
Physician: Rheumatology at Mayo Clinic



Get Report Now










Want to know more about Chris? Get a comprehensive background report, find full phone numbers, and other contact information when available, all from billions of available public records.
            Continue below for more details about Chris, or use our people search engine to find others.
Get Background Check on Chris M Storgard
Get a Criminal Check on Chris M Storgard
Get a Public Record Report on Chris M Storgard
Get a People Search Report on Chris M Storgard


Chris M Storgard's Contact Information
Known Cities Lived In
Find out where Chris M Storgard has lived as well as Chris M Storgard's phone numbers and email addresses.




Chris M Storgard Has Lived in 3 States
Minnesota Address for Chris M Storgard


200 1** S* S* 

Rochester, MN


Has Lived In

Rochester, MN
San Diego, CA


Get Full Address Report










Phone Numbers Associated with Chris M Storgard

(507) ***-**** - Rochester, MN 
(858) ***-**** - Cambridge, MA 


Get Full Phone Report



Email Addresses Associated with Chris M Storgard

c*******d@***.net
s************s@***.edu
c************d@***.com


Get Email Report




Chris M Storgard's Education Information
Known Schools Attended
Learn about Chris M Storgard's academic history.  Find out which schools Chris M Storgard attended, the dates attended as well as the degrees Chris M Storgard received.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Chris M Storgard Has Attended 3 Schools
Scripps Center for Integrative Medicine 1995 – 1997               Chris M Storgard has a Fellowship, in Rheumatology               
Scripps Center for Integrative Medicine               1995 – 1997               Chris M Storgard has a Fellowship, Rheumatology in Rheumatology               
University of Saskatchewan               1983 – 1991                              


Chris M Storgard's Professional Information
Information regarding Chris M Storgard's professional history.  Find out previous places Chris M Storgard has worked as well as dates employed.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Chris M Storgard Has Worked at 8 Places
Company: Mayo Clinic
               Title: Physician: Rheumatology
Company: Fate Therapeutics Inc
               Title: Cmo
Chris M Storgard's Experience
Title: Physician: Rheumatology
               Company: Mayo Clinic
Job Details
               Company Size: $1 bil and above - Employee Range: 25,000 to less than 100,000
Title: Cmo
               Company: Fate Therapeutics Inc
Job Details

Additional Professional Information on Chris M Storgard

 See Chris M Storgard's LinkedIn Profile



Chris M Storgard's Social Network and Potential Email Matches
Find out potential social network profiles and potential email usernamed for Chris M Storgard


Chris M Storgard's known Social Networks And Potential Email Matches

Find all of Chris M Storgard's Social Network Profiles

Get Full Report

Search Social Networks
Including Facebook, LinkedIn, MySpace, Google, Twitter, Yahoo, Jigsaw, ZoomInfo and more



Potential Email Matches
Chris Storgard
Username Matches

                  ChrisStorgard
                  StorgardChris
                  Chris.Storgard
                  Storgard.Chris
                  Chris_Storgard
                  Storgard_Chris
                  Chris-Storgard
                  Storgard-Chris
                  CStorgard
               


Popular Email Services

@gmail.com
@aol.com
@yahoo.com
@comcast.net
@hotmail.com
@msn.com
@rocketmail.com
@att.net
@sbcglobal.net
@ymail.com
@facebook.com
@mail.com
@bellsouth.net
@live.com
@earthlink.net
@cox.net
@prodigy.net
@me.com
@peoplepc.com
@juno.com
@rediffmail.com
@mindspring.com
@comcast.com
@charter.net
@outlook.com




All trademarks, product names, company names or logos on this page are the property of their respective owners.
Related People Searches
C Storgard







         Intelius is a leading provider of public data about people and their connections to others. Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the Fair Credit Reporting Act (FCRA). This site should not be used to determine an individual’s eligibility for credit, insurance, employment, housing or any other purpose covered by the FCRA. For employment or tenant screening services, please visit our partner Talentwise.
      

About Us
Site Map
About Our Reports
Blog
Help
Contact Us

© 2003 – 2017 PeopleConnect, Inc. d/b/a Intelius. All Rights Reserved.
         Privacy Policy - UPDATED
Terms of Service - UPDATED






What is the FCRA?
The Fair Credit Reporting Act ("FCRA") is a federal law that promotes the accuracy, fairness and privacy of information in the files of consumer reporting agencies.
Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the FCRA. Intelius reports cannot be used for background checks related to consumer credit, insurance, employment, housing or any other purpose
                  prohibited under the FCRA.
You may not use any information obtained from Intelius for any purpose covered by the FCRA.
Find out more about the FCRA here.
















          Ardea Biosciences  - About Us, Management Team    




























Skip to content


 


About Us 


Management Team                 
                    
                                        
             
Contact Us                  
                    
                                                            
             


News 
 
Careers 


Job Search                  
                    
                                                            
                                            
                                                            
            
                                          

View All Jobs                  
                    
                                                            
             
Post Resume                  
                    
                                                            
             
Member Login                  
                    
                                                            
             
View All Jobs                  
                    
                                                            
             
Working at Ardea                  
                    
                                                            
             
Benefits                  
                    
                                                            
             
Diversity                  
                    
                                                            
             
Location                  
                    
                                                            
             



Search Ardea Biosciences:









            About Us         




Page 'Sub' Navigation:

Management Team

Contact Us




Page Path 'Breadcrumb':


        Home

        About Us
Management Team

Management Team
James Mackay, PhDPresident & Chief Operating Officer
Dr. Mackay joined Ardea Biosciences in 2012 when AstraZeneca acquired the San Diego based biotech company. Dr. Mackay took over the role of President and Chief Operating Officer in 2013. Dr. Mackay has been instrumental to setting up an innovative model for Ardea Biosciences that has retained the biotech’s independence and accountability for the development of the gout franchise whilst also developing a synergistic and collaborative relationship with AstraZeneca. Prior to joining Ardea Biosciences, Dr. Mackay was Global Product Vice President for Onglyza/Kombiglyze XR at AstraZeneca and played a critical role in the successful development of the AstraZeneca/Bristol-Myers Squibb diabetes alliance. Dr. Mackay has a BS in Genetics and PhD in Medical Genetics from Aberdeen University, Scotland.

Jean-Luc Girardet, PhDVice President, Pharmaceutical & Translational Sciences
Dr. Girardet joined the Ardea Biosciences team in January 2007 as Senior Director of Discovery Logistics. He was promoted to the position of Vice President Research Operations in October 2007 and became responsible for all of the company’s drug discovery programs. After the selection of Ardea’s development compound RDEA3170 in 2010, his responsibilities have focused primarily on Chemistry & Development Support. Prior to joining Ardea, Dr. Girardet served as Associate Director of Chemistry and HIV Project Team Leader at Valeant Pharmaceuticals. In this role, he was in charge of selecting and advancing HIV NNRTI development candidates, as well as leading the Process Chemistry Group. In these functions, he was instrumental to bringing VRX-806 and VRX-119 (currently known as RDEA806 and RDEA119) into clinical development. Dr. Girardet joined Valeant in 2003 as part of its acquisition by Ribapharm. Prior to Ribapharm, Dr. Girardet had worked in the chemistry group at ICN Pharmaceuticals. He earned a PhD in Organic Chemistry from the University of Montpellier, France and completed Post-Doctoral studies at the University of Michigan, Ann Arbor. He is a coauthor of more than 40 scientific publications and book chapters and he holds more than 25 issued US patents.

John P. Montana, PMPVice President, Project Management & Finance
Mr. Montana joined Ardea Biosciences in November 2010, and is responsible for Project Leadership, Project Management and Strategic Planning. Prior to joining Ardea, Mr. Montana was the Vice President of Portfolio Management at Anadys Pharmaceuticals, with accountability to the CEO and Board of Directors for management of the development portfolio and budget. From January 2001 until June 2006, Mr. Montana was Executive Director and Head of Project Management at Pfizer La Jolla Labs. As a member of the Executive Leadership Team, Mr. Montana was responsible for a portfolio of over 35 development projects, including sunitinib (Sutent®), a multi-kinase inhibitor filed in 2006 and currently approved for use in life-threatening oncology indications. Prior to Pfizer's acquisition of the Warner-Lambert Company, Mr. Montana was a Project Leader and Manager at Agouron Pharmaceuticals, Inc., a division of the Warner-Lambert Company, since 1999. Mr. Montana joined Agouron in 1994 and was involved in both oncology and infectious disease projects, including nelfinavir (Viracept®), a protease inhibitor approved for the treatment of HIV. Mr. Montana also spent eight years at Genetic Systems-Sanofi prior to Agouron and was actively involved in the development and registration of blood screening diagnostic products, including one of the first rapid tests developed for HIV. He holds a BS in Microbiology/Immunology from the University of Washington, and is PMP certified.
Kristin MartinVice President, Human Resources, Facilities & IT
Ms. Martin joined Ardea Biosciences in May 2013 as the Executive Director of Human Resources. Prior to joining Ardea, Ms. Martin held senior human resources roles at Vantiv in Cincinnati, Ohio and Amylin Pharmaceuticals in San Diego, California and Cincinnati, Ohio. Ms. Martin has over 18 years of human resources experience across multiple industries. The majority of her career has been in the life sciences industry working with research and development as well as commercial operations and pharmaceutical manufacturing. Ms. Martin received her Bachelor’s degree from Bowling Green State University in Ohio.







Terms of Use
Privacy Policy
Site Map
About Us
News
Careers
Contact Us
 © Ardea Inc. 2014













Fate Therapeutics Appoints Chris M. Storgard, M.D. As Chief Medical Officer - TheStreet




































































 

 




















Action Alerts PLUS

Access AAPJim Cramer's Best Stocks for 2017Charitable Trust PortfolioMost Recent Trade Alert25 Investing Rules10 Trading Commandments

Real Money

Access RM25 Rules of InvestingJim Cramer's Best Stocks for 201710 CommandmentsStressed Out StocksCramer's Blog

Cramer
Mad Money
ETFs
Futures
Markets
Much More

BanksBiotechRetailTechPersonal FinanceRetirementFinancial Advisor CenterHow to SpendOptionsFixed IncomeVideo










Privacy Policy|Terms of Use© 1996- TheStreet Inc. All rights reserved
















                                DJIA
                            







                                NASDAQ
                            







                                S&P 500
                            






Market Data updated






Sign In




Your Membership(s)








Your Account





Account Preferences


Alerts


Newsletters







Subscribe





Logout



Subscribe

Access insights and guidance from our Wall Street pros. Find the product that's right for you.
Action Alerts PLUS
Action Alerts OPTIONS
Daily Swing Trade
Income Seeker
Quant Ratings
Real Money
Real Money Pro
Stocks Under $10
Top Stocks
Trifecta Stocks
Real Money Pro Portfolio
Chairman's Club
Compare All 
Chatter on the Street













































 








































Fate Therapeutics Appoints Chris M. Storgard, M.D. As Chief Medical Officer






GlobeNewswire



May 17, 2016 8:01 AM EDT













 




























































 SAN DIEGO, May 17, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Chris M. Storgard, M.D. has joined the Company as its Chief Medical Officer.  Dr. Storgard is an experienced drug development clinician with a proven history of advancing early stage programs through clinical development and product commercialization.  As CMO, he will lead the design and execution of the Company's clinical trials for its programmed cellular immunotherapies. "We are very pleased to welcome Chris during this exciting time for the Company as we work to deliver the significant promise of our adoptive immunotherapy programs," said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. "Chris brings extensive global clinical trial design and execution leadership to our organization, positioning us for success as we launch our Phase 1/2 clinical trial of ProTmune and advance our programmed immunotherapies for cancer and autoimmune disorders toward the clinic." Dr. Storgard has more than 20 years of experience in clinical drug development, most recently serving as an integral member of the executive team at Ardea Biosciences, a member of the AstraZeneca Group.  As Vice President of Clinical Research and Development at Ardea, Dr. Storgard led the ZURAMPIC® global clinical program to successful U.S. and European regulatory approvals. "I am excited to be joining the team at Fate Therapeutics at this pivotal point in the Company's evolution as we seek to rapidly and efficiently drive the clinical development of multiple ground-breaking immunotherapies," said Dr. Storgard. "It is a privilege to provide strategic and operational leadership to guide the advancement of novel therapies with the potential to address significant unmet medical needs and transform outcomes for millions of patients with cancer and autoimmune disorders."  



 








 










































If you liked this article you might like













The Setup Is Good for a Bounce, but it Hasn't Happened Yet
Some small names are interesting, but more-aggressive position trades are not developing right now.



Rev Shark

Mar 10, 2017 12:19 PM EST
























3 Small Biotechs With Insider Buying
Insiders have an edge in this complex sector, so it's worth checking them out.



Bret Jensen

Dec 29, 2016 10:00 AM EST
























On the Hunt for Holiday Movers
I'm still bullish, but I'm looking over my shoulder to see if there are some bears sneaking up.



Rev Shark

Nov 23, 2016 1:13 PM EST
























Rotation Is the Name of the Game
Traders are also looking for smaller-caps that can move big around the holiday.



Rev Shark

Nov 22, 2016 2:22 PM EST








































 











Trending


How Amazon Billionaire Jeff Bezos Gained Vast Riches and a Tech Giant Someday Worth $1 Trillion


Jim Cramer Nails Starbucks' Big Decline, Warns Again of Downside to $50


Here's Why Snap's Stock Could Be In For Another Big Plunge on Monday


Tesla's Model 3 Arrives on Friday -- Here's Everything You Need to Know About This Over-Hyped Ride


iPod Nano, Shuffle Are Dead; Here Are 8 Other Discontinued Apple Products











Advertising Partners



 






 






 






 


























 

























 































 


©1996-2017 TheStreet, Inc. All rights reserved.Action Alerts PLUS is a registered trademark of TheStreet, Inc.




Compare Brokers



 







 







 







 







 







 

















Chris Storgard, M.D. - Fate Therapeutics




























































Fate Therapeutics














Management

Chris Storgard, M.D.




Dr. Storgard is the Chief Medical Officer at Fate Therapeutics and is leading the company’s clinical development efforts. Dr. Storgard has more than 20 years of clinical research and pharmaceutical experience spanning from pre-clinical to Phase IV development. Previously, Dr. Storgard was the Vice President, Clinical Research and Development at Ardea Biosciences, a member of the AstraZeneca group, where he led the global clinical development of ZURAMPIC® to successful U.S. and European regulatory approvals. Before joining Ardea, he held senior positions in drug development and medical affairs at Prometheus Laboratories, Biogen Idec, and Amgen, where he focused on biologic and small molecule development programs within the inflammation and oncology teams. Dr. Storgard holds his M.D. from the University of Saskatchewan. He completed a fellowship in Rheumatology at Scripps Clinic and Research Center, and served as Senior Associate Consultant, Division of Rheumatology, and Assistant Professor and Member of the Molecular Medicine Program at the Mayo School of Medicine, Mayo Clinic in Minnesota.



















				MENU							



About Us

Our Mission
Our Cells of Interest
Management
Board of Directors


Pipeline

Overview
Immuno-Oncology Candidates

Fate-NK100
Engineered hnCD16iNK
Engineered CAR iT Cell


Immuno-Regulation Candidates

ProTmune™
ToleraCyte™




Science

Ex Vivo Cell Modulation
iPSC Product Platform
ISSCR Annual Meeting and Presentations

ISSCR 2016 Annual Meeting




Collaborations
Join Our Team

Career Opportunities
Vision, Mission, Values
Working at Fate


Investors

Overview
Press Releases
Events & Presentations
Financials & Filings

SEC Filings
Annual Reports and Proxies


Corporate Governance
Stock Information

Historical Stock Lookup


Investors FAQs


Contact






Fate Therapeutics Appoints Storgard as Chief Medical Officer | San Diego Business Journal



































San Diego Business Journal





home
news



print
email



Fate Therapeutics Appoints Storgard as Chief Medical Officer

      By Brittany Meiling


      Tuesday, May 17, 2016
		





Tweet

    








        Chief Medical Officer Dr. Chris Storgard of Fate Therapeutics 
        
      

San Diego’s Fate Therapeutics Inc. has appointed a new chief medical officer in charge of clinical trial design and execution, the company announced Tuesday.
Dr. Chris M. Storgard joined Fate Therapeutics from San Diego-based Ardea Biosciences Inc., an AstraZeneca company, where he was vice president of clinical research and development. Storgard led global clinical trial programs for the AstraZeneca drug Zurampic, which later passed regulatory approval in the U.S. and Europe.
At Fate, Storgard will lead the company’s programmed cellular immunotherapy clinical trials, including its lead product candidate ProTmune.
“Chris brings extensive global clinical trial design and execution leadership to our organization, positioning us for success as we launch our Phase 1/2 clinical trial of ProTmune and advance our programmed immunotherapies for cancer and autoimmune disorders toward the clinic,” said Scott Wolchko, president and CEO of Fate Therapeutics, in a statement.
Before joining Ardea in 2011, Storgard held senior positions in drug development and medical affairs at Prometheus Laboratories Inc., Biogen Inc., and Amgen Inc., where he focused on biologic and small molecule development programs within the inflammation and oncology teams, according to a Fate news release. 
Storgard holds his M.D. from the University of Saskatchewan.  He also completed a fellowship in Rheumatology at Scripps Clinic and Research Center.
Fate Therapeutics (Nasdaq: FATE), a thinly traded public company with a market cap of about $43 million, is currently trading for $1.53 per share.

































you may also like


Fate Therapeutics Raises $10.3 Million
AstraZeneca to Acquire Biotech In $1.26B Deal
AstraZeneca to Acquire Local Biotech for $1.26B
OncoSec Medical Makes Appointment to Its Scientific Advisory Board
Retrophin Brings on Ex-Ardea Executive to Lead R&D
Fate Therapeutics CEO Christian Weyer Resigns, Scott Wolchko Named Successor 
Jerome Zeldis Named CMO at Sorrento Therapeutics 
Ardea Biosciences to Close, Lay Off 145 Employees







 






HOME
LISTS
FINANCE
HEALTHCARE
MANUFACTURING
REAL ESTATE
SERVICES
TECHNOLOGY
DEFENSE
TRAVEL/LEISURE













BROWSE MORE

Classified
The Lists Archives
Poll Archive



LEARN MORE

About Us
Privacy Policy
Contact Us
Edit Profile



SERVICES

Subscription Center
Online Login/Register
Advertise with Us
Sign-Up for E-News Updates
Retail/Newsstand Locations



TOOLS

Calendar
Robert Half Jobs Search 



OTHER JOURNALS

Los Angeles Business Journal
Orange County Business Journal
San Fernando Valley Business Journal



© 2017 San Diego Business Journal 

		

		

		

		Phone: 1-858-277-6359 



Los Angeles Business Journal
Orange County Business Journal
San Fernando Valley Business Journal
San Diego Business Journal





   

			

Subscribe

Print Edition
Renewals
Edit Your Subscription Account
Email News Updates
RSS Headlines Feed



Advertise

Online Display Ads
Business Marketplace
Supplements
Ascent



Events



						

						

						SD Business Events

						

					



The Lists

The Book of Lists



Resources

Supplements
WebConnect
Marketplace
Ascent
Email News Updates
RSS Headlines Feed
Robert Half Jobs Search



About Us




						

						

						SDBJ

						

					

Staff
Privacy Policy
Contact Us
Newsstand Locations
Edit Profile


login







	Fate Therapeutics Appoints Chris M Storgard M D As Chief Medical Officer













































Employer:
Login
Post Jobs


Job Seeker:
Login
Sign Up

























Search Life Sciences Jobs





Search Job Title Only












Radius:
Miles



Km80.5
















                 News | News By Subject | News by Disease |  
    News By Date | Search News



















Get Our FREEIndustry eNewsletter

email:


*
            
*
            



















 

 






Fate Therapeutics (FATE) Appoints Chris M. Storgard, M.D. As Chief Medical Officer  











Tweet








5/17/2016 8:20:35 AM




  Life Sciences Jobs
 


  &bullet; Newest Jobs - Last 24 Hours


  &bullet; California Jobs


  &bullet; Massachusetts Jobs


  &bullet; New Jersey Jobs


  &bullet; Maryland Jobs


  &bullet; Washington Jobs


  View More Jobs


 SAN DIEGO, May 17, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Chris M. Storgard, M.D. has joined the Company as its Chief Medical Officer.  Dr. Storgard is an experienced drug development clinician with a proven history of advancing early stage programs through clinical development and product commercialization.  As CMO, he will lead the design and execution of the Company’s clinical trials for its programmed cellular immunotherapies. “We are very pleased to welcome Chris during this exciting time for the Company as we work to deliver the significant promise of our adoptive immunotherapy programs,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. “Chris brings extensive global clinical trial design and execution leadership to our organization, positioning us for success as we launch our Phase 1/2 clinical trial of ProTmune and advance our programmed immunotherapies for cancer and autoimmune disorders toward the clinic.” Dr. Storgard has more than 20 years of experience in clinical drug development, most recently serving as an integral member of the executive team at Ardea Biosciences, a member of the AstraZeneca Group.  As Vice President of Clinical Research and Development at Ardea, Dr. Storgard led the ZURAMPIC® global clinical program to successful U.S. and European regulatory approvals. “I am excited to be joining the team at Fate Therapeutics at this pivotal point in the Company’s evolution as we seek to rapidly and efficiently drive the clinical development of multiple ground-breaking immunotherapies,” said Dr. Storgard. “It is a privilege to provide strategic and operational leadership to guide the advancement of novel therapies with the potential to address significant unmet medical needs and transform outcomes for millions of patients with cancer and autoimmune disorders.” Before joining Ardea in 2011, Dr. Storgard held senior positions in drug development and medical affairs at Prometheus Laboratories, Biogen Idec, and Amgen, where he focused on biologic and small molecule development programs within the inflammation and oncology teams.  Dr. Storgard holds his M.D. from the University of Saskatchewan.  He also completed a fellowship in Rheumatology at Scripps Clinic and Research Center, and served as Senior Associate Consultant, Division of Rheumatology, and Assistant Professor and Member of the Molecular Medicine Program at the Mayo School of Medicine, Mayo Clinic in Minnesota. In connection with Dr. Storgard’s appointment, the Company granted Dr. Storgard an option to purchase 200,000 shares of the Company’s common stock with an exercise price equal to $1.54, the closing price per share of the Company’s common stock as reported by NASDAQ on the effective date of grant, May 16, 2016, which was the date Dr. Storgard’s employment began.  The option is a non-qualified stock option and vests over a period of four years, with 25 percent vesting on the one year anniversary of the grant date and the remaining 75 percent in approximately equal monthly increments over the succeeding thirty-six months, subject to Dr. Storgard’s continuous employment through each vesting date. This award was granted as an inducement material to Dr. Storgard’s entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4), and was granted pursuant to the Fate Therapeutics, Inc. Inducement Equity Plan.  The Company has reserved an aggregate of 500,000 shares of its common stock (including the shares underlying the option granted to Dr. Storgard) for issuance under the Inducement Equity Plan, which was approved by the Company’s Board of Directors on May 10, 2016.  About Fate Therapeutics, Inc. Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline is comprised of immuno-oncology programs, including off-the-shelf NK- and T-cell cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its adoptive cell therapy programs are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.  Forward-Looking Statements   This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s advancement of and plans related to, the Company’s product candidates and research and development programs. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company may cease or delay preclinical or clinical development activities for any of its existing or future product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities and requirements for regulatory approval, difficulties or delays in patient enrollment in current and planned clinical trials, and any adverse events or other negative results that may be observed during preclinical or clinical development). For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Company’s periodic filings with the Securities and Exchange Commission, including but not limited to the Company’s most recently filed periodic report, and from time to time the Company’s other investor communications. Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.   Contact: Jesse Baumgartner Stern Investor Relations, Inc. 212.362.1200 jesse@sternir.com     






                Read at
                BioSpace.com







Related News
Fate Therapeutics (FATE) Announces Preclinical Data Highlighting Persistent Effector Function Of Allogeneic Natural Killer Cell Cancer Immunotherapy  Another Director, Accounting Firm Quit Navidea (NAVB), Lender Tried to Freeze Its Bank Accounts  Fate Therapeutics (FATE) Reports First Quarter 2016 Financial Results  Facebook's Oculus Rift Developer Resigns to Work on Wearable MRI Startup  Fate Therapeutics (FATE) To Webcast Conference Call Reporting First Quarter 2016 Financial Results On May 9, 2016  Meet The Man Whose Biotech Is Trying To Bring People Back From The Dead  Fate Therapeutics (FATE) To Present Preclinical Data For Protmune At 2016 BMT Tandem Meetings  Pernix (PTX) CEO Steps Down, Effectively Immediately  Fate Therapeutics (FATE) Announces FDA Clearance Of Investigational New Drug Application For Protmune For Prevention Of Acute Gvhd And CMV Infection  Theranos COO Abruptly Resigns, Company Adds New Board Members  




Please enable JavaScript to view the comments powered by Disqus.
comments powered by Disqus






















                            •
                            BioSpace.com










                            •
                            Fate Therapeutics




             
        





                            •
                            Biotech/Pharma - Personnel




             
        















                              
                            

                              
                             
                              
                            

                              
                            








                 





























